Antipsychotics as antidepressants

Asia-Pacific Psychiatry

Volumn 8, Issue 3, 2016, Pages 179-188

  Roberts, Rona Jeannie ^a   Lohano, Kavita K ^a   El Mallakh, Rif S ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

antidepressant medication; antipsychotic medication; bipolar disorder; major depression; mood disorder

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; ZIPRASIDONE;

ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; DEPRESSION; DRUG EFFICACY; DYSPHORIA; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANQUILIZING ACTIVITY;

EID: 84978877443     PISSN: 17585864     EISSN: 17585872     Source Type: Journal    
DOI: 10.1111/appy.12186     Document Type: Review

References (78)

1. Amsterdam J.D. (1992) Gepirone, a selective serotonin (5HT1A) partial agonist in the treatment of major depression. Prog Neuropsychopharmacol Biol Psychiatry. 16, 271–280.
2. Azorin J.M., Sapin C., Weiller E. (2013) Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord. 145, 62–69.
3. Barnett S.D., Kramer M.L., Casat C.D., Connor K.M., Davidson J. (2002) Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 16, 365–368.
4. Bartzokis G., Lu P.H., Turner J., Mintz J., Saunders C.S. (2005) Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 57, 474–479.
5. Bauer M., Pretorius H.W., Constant E.L., Earley W.R., Szamosi J., Brecher M. (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 70, 540–549.
6. Berman R.M., Marcus R.N., Swanink R., et al. (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 68, 843–853.
7. Berman R.M., Fava M., Thase M.E., et al. (2009) Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 14, 197–206.
8. Bersani G., Pozzi F., Marini S., Grispini A., Pasini A., Ciani N. (1991) 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand. 83, 244–248.
9. Brawman-Mintzer O., Knapp R.G., Nietert P.J. (2005) Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 66, 1321–1325.
10. Bressa G.M., Marini S., Gregori S. (1987) Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam. Int J Clin Pharmacol Res. 7, 111–119.
11. Brunelli S.A., Aviles J.A., Gannon K.S., Branscomb A., Shacham S. (2009) PRX-00023, a selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in infant rats bred for high infantile anxiety. Pharmacol Biochem Behav. 94, 8–15.
12. Brüning C.A., Prigol M., Roehrs J.A., Nogueira C.W., Zeni G. (2009) Involvement of the serotonergic system in the anxiolytic-like effect caused by m-trifluoromethyl-diphenyl diselenide in mice. Behav Brain Res. 205, 511–517.
13. Bystritsky A., Ackerman D.L., Rosen R.M., et al. (2004) Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 65, 565–568.
14. Carey P., Suliman S., Ganesan K., Seedat S., Stein D.J. (2012) Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Hum Psychopharmacol. 27, 386–391.
15. Ceulemans D.L., Hoppenbrouwers M.L., Gelders Y.G., Reyntjens A.J. (1985) The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry. 18, 303–305.
16. Corya S.A., Perlis R.H., Keck P.E. Jr, et al. (2006) A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry. 67, 798–806.
17. Cunningham K.A., Fox R.G., Anastasio N.C., et al. (2011) Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues. Neuropharmacology. 61, 513–523.
18. Dubé S., Tollefson G.D., Thase M.E., et al. (2007) Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord. 9, 618–627.
19. Duncan M.J., Grear K.E., Hoskins M.A. (2004) Aging and SB-269970-A, a selective 5-HT7 receptor antagonist, attenuate circadian phase advances induced by microinjections of serotonergic drugs in the hamster dorsal raphe nucleus. Brain Res. 1008, 40–48.
20. El-Khalili N., Joyce M., Atkinson S., et al. (2010) Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 13, 917–932.
21. Fabre L.F., Smith L.C., DeRogatis L.R. (2011) Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain – a post hoc analysis. J Sex Med. 8, 2569–2581.
22. Fava M., Mischoulon D., Iosifescu D., et al. (2012) A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Published erratum appears in 2012 Psychother. Psychosom. 81(4), 261. Psychother Psychosom. 81, 87–97.
23. Harada K., Aota M., Inoue T., et al. (2006) Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur J Pharmacol. 553(1–3), 171–184.
24. 1A receptor activity. J Pharmacol Exp Ther. 334, 171–181.
25. Jensen N.H., Rodriguiz R.M., Caron M.G., Wetsel W.C., Rothman R.B., Roth B.L. (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 33, 2303–2312.
26. Katila H., Mezhebovsky I., Mulroy A., et al. (2013) Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. 21, 769–784.
27. Keck P.E. Jr, Corya S.A., Altshuler L.L., et al. (2005) Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry. 66, 611–616.
28. Keitner G.I., Garlow S.J., Ryan C.E., et al. (2009) A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res. 43, 205–214.
29. Khan A., Joyce M., Atkinson S., Eggens I., Baldytcheva I., Eriksson H. (2011) A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 31, 418–428.
30. King D.J., Burke M., Lucas R.A. (1995) Antipsychotic drug-induced dysphoria. Br J Psychiatry. 167, 480–482.
31. Krakowski M.I., Czobor P., Citrome L., Bark N., Cooper T.B. (2006) Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 63, 622–629.
32. Krystal J.H., Rosenheck R.A., Cramer J.A., et al. (2011) Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 306, 493–502.
33. LaLonde C.D., Van Lieshout R.J. (2011) Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 31, 326–333.
34. Lin C., Lin S., Jang F. (2011) Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder. J Clin Psychopharmacol. 31, 563–568.
35. Loebel A., Cucchiaro J., Silva R., et al. (2014a) Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 171, 160–168.
36. Loebel A., Cucchiaro J., Silva R., et al. (2014b) Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 171, 169–177.
37. Lohoff F.W., Etemad B., Mandos L.A., Gallop R., Rickels K. (2010) Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 30, 185–189.
38. Lombardo I., Sachs G., Kolluri S., Kremer C., Yang R. (2012) Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol. 32, 470–478.
39. Lydiard R.B., Culpepper L., Schiöler H., Gustafsson U., Paulsson B. (2009) Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double-blind, randomized, placebo-controlled studies. Prim Care Companion J Clin Psychiatry. 11, 215–225.
40. Maneeton N., Maneeton B., Srisurapanont M., Martin S.D. (2012) Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 12, 160.
41. Marcus R.N., McQuade R.D., Carson W.H., et al. (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 28, 156–165.
42. McDonagh M., Peterson K., Carson S., Fu R., Thakurta S. (2010) Drug Class Review: Atypical Antipsychotic Drugs. Oregon Health & Science University, Portland, OR. Final update 3 report. 2010 Jul. [Cited February 2013.] Available from URL: http://www.ncbi.nlm.nih.gov/books/NBK50583/
43. McElroy S.L., Weisler R.H., Chang W., et al. (2010) A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 71, 163–174.
44. McIntyre A., Gendron A., McIntyre A. (2007) Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 24, 487–494.
45. Meltzer H.Y., Matsubara S., Lee J.C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 251, 238–246.
46. Meltzer H.Y., Alphs L., Green A.I., et al. (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Published erratum appears in 2003 Arch. Gen. Psychiatry 60(7), 735. Arch Gen Psychiatry. 60, 82–91.
47. Merideth C., Cutler A.J., She F., Eriksson H. (2012) Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 27, 40–54.
48. Mezhebovsky I., Mägi K., She F., Datto C., Eriksson H. (2013) Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry. 28, 615–625.
49. Mischoulon D., Witte J., Levy M., et al. (2012) Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 73, 353–357.
50. Miyamoto S., Duncan G.E., Goff D.C., Lieberman J.A. (2002) Therapeutics of schizophrenia, Chapter 56. In: Davis K., Charney D., Coyle J., Nemeroff C., eds. Neuropscyhophramacology: The Fifth Generation of Progress. The American College of Neuropscyhopharmacology. Lippincott Williams and Wilkens, Philadelphia, PA, pp. 775–808.
51. Mnie-Filali O., Faure C., Lambás-Señas L., et al. (2011) Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology. 36, 1275–1288.
52. Monti J.M., Leopoldo M., Jantos H. (2008) The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat. Behav Brain Res. 191, 184–189.
53. Moreau J.L., Griebel G., Jenck F., Martin J.R., Widmer U., Haefely W.E. (1992) Behavioral profile of the 5HT1A receptor antagonist (S)-UH-301 in rodents and monkeys. Brain Res Bull. 29, 901–904.
54. Padala P.R., Madison J., Monnahan M., et al. (2006) Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol. 21, 275–280.
55. Patkar A.A., Pae C.U. (2013) Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 27, S29–S37.
56. Pollack M.H., Simon N.M., Zalta A.K., et al. (2006) Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 59, 211–215.
57. Pubchem (2012) BioActivity data for compound ziprasidone (CID 60854). [Cited 10 October 2012.] Available from URL: http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?cid=60854
58. Reeves H., Batra S., May R.S., Zhang R., Dahl D.C., Li X. (2008) Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 69, 1228–1336.
59. Robinson D.S., Rickels K., Feighner J., et al. (1990) Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol. 10(3 Suppl), 67S–76S.
60. Rothschild A.J., Williamson D.J., Tohen M.F., et al. (2004) A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 24, 365–373.
61. Sanford M., Keating G.M. (2012) Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs. 26, 435–460.
62. 7 receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res. 209, 99–108.
63. Sheehan D.V., McElroy S.L., Harnett-Sheehan K., et al. (2009) Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord. 115, 376–385.
64. Sheehan D.V., Harnett-Sheehan K., Hidalgo R.B., et al. (2013) Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J Affect Disord. 145, 83–94.
65. Stahl S.M., Shayegan D.K. (2003) The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 64(Suppl 19), 6–12.
66. Szegedi A., Zhao J., van Willigenburg A., Nations K.R., Mackle M., Panagides J. (2011) Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry. 11, 101.
67. Thase M.E., Haight B.R., Richard N., et al. (2005) Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 66, 974–981.
68. Thase M.E., Demyttenaere K., Earley W.R., Gustafsson U., Udd M., Eriksson H. (2012) Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 29, 574–586.
69. Tohen M., Vieta E., Calabrese J., et al. (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 60, 1079–1088.
70. Tohen M., Calabrese J., Vieta E., et al. (2007) Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord. 104(1–3), 137–146.
71. Tohen M., Case M., Trivedi M.H., Thase M.E., Burke S.J., Durell T.M. (2010) Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 71, 451–462.
72. Weisler R., Joyce M., McGill L., et al. (2009) Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 14, 299–313.
73. Weisler R.H., Nolen W.A., Neijber A., Hellqvist A., Paulsson B., Trial 144 Study Investigators (2011) Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). Clin Ther. 33, 1643–1658.
74. Weisler R.H., Montgomery S.A., Earley W.R., Szamosi J., Lazarus A. (2012) Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 27, 27–39.
75. 7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology. 51, 578–586.
76. Wesołowska A., Nikiforuk A., Stachowicz K. (2006b) Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats. Eur J Pharmacol. 553(1–3), 185–190.
77. Yocca F.D. (1990) Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors. J Clin Psychopharmacol. 10(3 Suppl), 6S–12S.
78. Young A.H., McElroy S.L., Bauer M., et al. (2010) A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 71, 150–162.